Patent US7842729B2 successfully refreshed from Google Patents.
US7842729B2
Expired / Lapsed
US
⏱️ 0.0 years remaining
Anti tubercular drug: compositions and methods
Assignee: Sequella Inc
•
Filing: 2005-06-03
•
Granted: 2010-11-30
•
Expires: 2025-06-03
Abstract
Abstract Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.
Inventors
- 👤 Marina Nikolaevna Protopopova
- 👤 Richard Edward Lee
- 👤 Richard Allan Slayden
- 👤 Clifton E. Barry, III
- 👤 Elena Bogatcheva
- 👤 Leo Einck
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 21:35
CPC Classifications
C; C07; C07C; C07C323/00; C07C323/23; C07C323/24; C07C323/25; A; A61; A61K; A61K31/00; A61K31/13; A61K31/132; A61K31/133; A61K31/135; A61K31/137; A61K31/33; A61K31/395; A61K31/40; A61K31/435; A61K31/44; A61K31/445; A61P; A61P1/00; A61P1/04; A61P11/00; A61P31/00; A61P31/04; A61P31/06; A61P31/10; A61P31/12; A61P33/00; C07C211/00; C07C211/01; C07C211/26; C07C211/27; C07C211/29; C07C211/33; C07C211/34; C07C211/35; C07C211/39; C07C211/41; C07C211/42; C07C215/00; C07C215/02; C07C215/04; C07C215/06; C07C215/14; C07C215/22; C07C215/28; C07C215/30; C07C215/46; C07C215/56; C07C215/58; C07C215/60; C07C217/00; C07C217/02; C07C217/04; C07C217/06; C07C217/08; C07C217/10; C07C217/54; C07C217/56; C07C217/58; C07C217/60; C07C217/62; C07C323/46; C07C323/47; C07D; C07D211/00; C07D211/04; C07D211/06; C07D211/36; C07D211/40; C07D211/44; C07D211/46; C07C2601/00; C07C2601/02; C07C2601/06; C07C2601/08; C07C2601/12; C07C2601/14; C07C2601/16; C07C2601/18; C07C2602/00; C07C2602/02; C07C2602/04; C07C2602/10; C07C2602/36; C07C2602/42; C07C2603/00; C07C2603/56; C07C2603/58; C07C2603/70; C07C2603/74; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 27
Claim 1
Independent Claim
119 words
A method of treating disease caused by a mycobacterial agent, comprising administering to a human or a non-human animal an effective amount of a substituted ethylene diamine compound of the formula: wherein R 4 is selected from H, alkyl, aryl, alkenyl, alkynyl, aralkyl, aralkynyl, cycloalkyl, cycloalkenyl; and wherein R 1 , R 2 and R 3 are independently selected from H, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkenyl, halide, alkoxy, aryloxy, alkylthio, arylthio, silyl, siloxy, amino, heteroaryl or aryl; or wherein when R 1 is selected from H, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkenyl, halide, alkoxy, aryloxy, alkylthio, arylthio, silyl, siloxy, amino, and NR 2 R 3 is a cyclic secondary amine; or a pharmaceutically acceptable salt thereof.
Claim 2
Independent Claim
119 words
A method of treating disease caused by a mycobacterial agent, comprising administering to a human or a non-human animal an effective amount of a substituted ethylene diamine compound of the formula: wherein R 4 is selected from H, alkyl, aryl, alkenyl, alkynyl, aralkyl, aralkynyl, cycloalkyl, cycloalkenyl; and wherein R 1 , R 2 and R 3 are independently selected from H, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkenyl, halide, alkoxy, aryloxy, alkylthio, arylthio, silyl, siloxy, amino, heteroaryl or aryl; or wherein when R 1 is selected from H, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkenyl, halide, alkoxy, aryloxy, alkylthio, arylthio, silyl, siloxy, amino, and NR 2 R 3 is a cyclic secondary amine; or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
48 words
The method of claim 1 , wherein the mycobacterial agent comprises M. tuberculosis, M. avium - intracellulare, M. kansasii, M. fortuitum, M. chelonae, M. leprae, M. africanum, M. bovis, M. avium, M. microti, M. avium paratuberculosis, M. intracellulare, M. scrofulaceum, M. xenopi, M. marinnur , or M. ulcerans.
Claim 4
Dependent Claim
13 words
The method of claim 1 , wherein the disease is tuberculosis or leprosy.
Claim 5
Independent Claim
37 words
A method of treating disease caused by a mycobacterial agent, comprising administering to a human or a non-human animal an effective amount of a substituted ethylene diamine compound of the formula or a pharmaceutically acceptable salt thereof.
Claim 6
Independent Claim
37 words
A method of treating disease caused by a mycobacterial agent, comprising administering to a human or a non-human animal an effective amount of a substituted ethylene diamine compound of the formula or a pharmaceutically acceptable salt thereof.
Claim 7
Dependent Claim
11 words
The method of claim 4 , further comprising a pharmaceutical carrier.
Claim 8
Independent Claim
29 words
A method for treating a disease caused by a mycobacterial agent, comprising administering to a human or a non-human animal a pharmaceutically effective amount of a compound of formula
Claim 9
Independent Claim
29 words
A method for treating a disease caused by a mycobacterial agent, comprising administering to a human or a non-human animal a pharmaceutically effective amount of a compound of formula
Claim 10
Dependent Claim
11 words
The method of claim 6 , further comprising a pharmaceutical carrier.
Claim 11
Dependent Claim
13 words
The method of claim 6 , wherein the disease is leprosy or tuberculosis.
Claim 12
Dependent Claim
16 words
The method of claim 1 , wherein the mycobacterial agent is a drug resistant mycobacterial strain.
Claim 13
Dependent Claim
16 words
The method of claim 6 , wherein the mycobacterial agent is a drug resistant mycobacterial strain.
Claim 14
Dependent Claim
32 words
The method of claim 1 , wherein the effective amount of substituted ethylene diamine compound is administered topically, orally, peritoneally, subcutaneously, intramuscularly, intraocularly, intraarterially, intravenously, or locally using an implantable dosage unit.
Claim 15
Dependent Claim
20 words
The method of claim 1 , wherein the substituted ethylene diamine compound is administered as a solid, liquid or aerosol.
Claim 16
Dependent Claim
21 words
The method of claim 12 , wherein the solid is a pill, a cream, a soap or an implantable dosage unit.
Claim 17
Dependent Claim
20 words
The method of claim 12 , wherein the liquid is a liquid formulation adapted for injection, topical or ocular administration.
Claim 18
Dependent Claim
13 words
The method of claim 12 , wherein the aerosol comprises an inhaler formulation.
Claim 19
Dependent Claim
17 words
The method of claim 12 , wherein the solid, liquid or aerosol comprises a sustained release matrix.
Claim 20
Dependent Claim
26 words
The method of claim 1 , wherein the effective amount of substituted ethylene diamine compound comprises from 100 to 0.1 mg per kg of body weight.
Claim 21
Dependent Claim
26 words
The method of claim 1 , wherein the effective amount of substituted ethylene diamine compound comprises from 50 to 0.2 mg per kg of body weight.
Claim 22
Dependent Claim
26 words
The method of claim 1 , wherein the effective amount of substituted ethylene diamine compound comprises from 25 to 0.5 mg per kg of body weight.
Claim 23
Dependent Claim
21 words
The method of claim 1 , wherein the effective amount of substituted ethylene diamine compound comprises from 1 to 1000 mg.
Claim 24
Dependent Claim
16 words
The method of claim 4 , wherein the mycobacterial agent is a drug resistant mycobacterial strain.
Claim 25
Dependent Claim
48 words
The method of claim 4 , wherein the mycobacterial agent is M. tuberculosis, M. avium - intracellulare, M kansarii, M. fortuitum, M chelonae, M. leprae, M africanum, M. bovis, M avium, M. microti, M. avium paratuberculosis, M. intracellulare, M scrofulaceum, M. xenopi, M. marinum , or M. ulcerans.
Claim 26
Dependent Claim
47 words
The method of claim 6 , wherein the mycobacterial_agent is M. tuberculosis, M. avium - intracellulare, M kansarii, M. fortuitum, M chelonae, M. leprae, M africanum, M. bovis, M avium, M. microti, M. avium paratuberculosis, M. intracellulare, M scrofulaceum, M. xenopi, M. marianum , or M. ulcerans.
Claim 27
Dependent Claim
13 words
The method of claim 4 , wherein the disease is leprosy or tuberculosis.
References Cited (Backward Citations)
US526391A
Cited
US2709169A
Cited
US2623878A
Cited
GB961317A
Cited
US3176040A
Cited
US3463861A
Cited
US3197468A
Cited
BE669202A
Cited
GB1157143A
Cited
USRE29588E
Cited
US3553257A
Cited
US3579587A
Cited
US3876702A
Cited
FR2007524A1
Cited
US3579586A
Cited
US3682922A
Cited
GB1234349A
Cited
US3718655A
Cited
US3629333A
Cited
US3789073A
Cited
US3769347A
Cited
US3878201A
Cited
US3847991A
Cited
US3829493A
Cited
USRE29358E
Cited
US3855300A
Cited
US3979457A
Cited
US3953513A
Cited
US3931152A
Cited
US3944616A
Cited
US4006234A
Cited
US3931157A
Cited
US4150030A
Cited
US3944619A
Cited
US3944617A
Cited
US3944618A
Cited
US3944608A
Cited
SU803348A1
Cited
SU805605A1
Cited
US4262122A
Cited
US4450274A
Cited
US4457931A
Cited
US5104875A
Cited
WO1991010664A1
Cited
WO1993010073A1
Cited
US5985935A
Cited
WO1994028885A1
Cited
US5439891A
Cited
US5864045A
Cited
US5922282A
Cited
WO1999051213A2
Cited
US20030069204A1
Cited
US20030171330A1
Cited
US6660744B1
Cited
US20020007524A1
Cited
CA2409741A1
Cited
RU2168986C1
Cited
US20040147591A1
Cited
US20050014800A1
Cited
WO2003068769A1
Cited
US20040058964A1
Cited
US20030236225A1
Cited
US20040033986A1
Cited
US7456222B2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2013-11-29 | 2014-05-31 | 2014-11-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2017-11-29 | 2018-05-31 | 2018-11-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2021-11-29 | 2022-05-31 | 2022-11-30 | $7700.00 | Window Closed / Lapsed |